论文部分内容阅读
肝细胞肝癌位列全世界肿瘤发病率第5位,在我国,其发病率及病死率均居恶性肿瘤的第2位,此外,肝癌术后5年的累计复发率为77%～100%[1]。门静脉癌栓(portal vein tumor thrombus,PVTT)形成是肝癌的生物学特征之一,也是肝癌术后复发和肝内播散的主要原因。临床报道肝癌合并PVTT发生率为44.0%～62.2%[2],无干预情况下中位生存期仅为2.7个月[3]。对于该类患者的处理,以往
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. In China, the morbidity and mortality are the second among malignant tumors. In addition, the cumulative recurrence rate of hepatocellular carcinoma after 5 years is 77% -100% [ 1]. The formation of portal vein tumor thrombus (PVTT) is one of the biological characteristics of liver cancer, and is also the main reason for postoperative recurrence and intrahepatic dissemination of liver cancer. The incidence of hepatocellular carcinoma with PVTT in clinical reports ranged from 44.0% to 62.2% [2], with a median survival of only 2.7 months without intervention [3]. For the treatment of such patients, in the past